The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial
Open accessAbstract
Importance: Previous research suggested that soluble human recombinant thrombomodulin may reduce mortality among patients with sepsis-associated coagulopathy. Objective: To determine the effect of human recombinant thrombomodulin vs placebo on 28-day all-cause mortality among patients with sepsis-associated coagulopathy. Design, Setting, and Participants: The SCARLET trial was a randomized, double-blind, placebo-controlled, multinational, multicenter phase 3 study conducted in intensive care units at 159 sites in 26 countries. All adult patients admitted to one of the participating intensive care units between October 2012 and March 2018 with sepsis-associated coagulopathy and concomitant cardiovascular and/or respiratory failure, defined as an international normalized ratio greater than 1.40 without other known etiology and a platelet count in the range of 30 to 150 × 109/L or a greater than 30% decrease in platelet count within 24 hours, were considered for inclusion. The final date of follow-up was February 28, 2019. Interventions: Patients with sepsis-associated coagulopathy were randomized and treated with an intravenous bolus or a 15-minute infusion of thrombomodulin (0.06 mg/kg/d [maximum, 6 mg/d]; n = 395) or matching placebo (n = 405) once daily for 6 days. Main Outcome and Measures: The primary end point was 28-day all-cause mortality. Results: Among 816 randomized patients, 800 (mean age, 60.7 years; 437 [54.6%] men) completed the study and were included in the full analysis set. In these patients, the 28-day all-cause mortality rate was not statistically significantly different between the thrombomodulin group and the placebo group (106 of 395 patients [26.8%] vs 119 of 405 patients [29.4%], respectively; P = .32). The absolute risk difference was 2.55% (95% CI, -3.68% to 8.77%). The incidence of serious major bleeding adverse events (defined as any intracranial hemorrhage; life-threatening bleeding; or bleeding event classified as serious by the investigator, with administration of at least 1440 mL [typically 6 units] of packed red blood cells over 2 consecutive days) was 23 of 396 patients (5.8%) in the thrombomodulin group and 16 of 404 (4.0%) in the placebo group. Conclusions and Relevance: Among patients with sepsis-associated coagulopathy, administration of a human recombinant thrombomodulin, compared with placebo, did not significantly reduce 28-day all-cause mortality. Trial Registration: ClinicalTrials.gov Identifier: NCT01598831.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The epidemiology of sepsis in the United States from 1979 through 2000
Martin, G. S., Mannino, D. M., Eaton, S., & Moss, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022139 · Cited by 5,841
Drotrecogin Alfa (Activated) in Adults with Septic Shock
Ranieri, V. M., Thompson, B. T., Barie, P. S., Dhainaut, J.-F., Douglas, I. S., Finfer, S., Gårdlund, B., Marshall, J. C., Rhodes, A., Artigas, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202290 · Cited by 1,309
Self-citationDhainaut, J. ‐., Yan, S. B., Joyce, D. E., Pettilä, V., Basson, B., Brandt, J. T., Sundin, D. P., & Levi, M. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00955.x · Cited by 426
Self-citationVincent, J.-L., Ramesh, M. K., Ernest, D., LaRosa, S. P., Pachl, J., Aikawa, N., Hoste, E., Levy, H., Hirman, J., Levi, M., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31828e9b03 · Cited by 320
Self-citationProteolytic Cleavage of High Mobility Group Box 1 Protein by Thrombin-Thrombomodulin Complexes
Ito, T., Kawahara, K.-I., Okamoto, K., Yamada, S., Yasuda, M., Imaizumi, H., Nawa, Y., Meng, X., Shrestha, B., Hashiguchi, T., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.150631 · Cited by 206
Opal, S. M., Dellinger, R. P., Vincent, J.-L., Masur, H., & Angus, D. C. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000325 · Cited by 191
Self-citationSepsis-Associated Coagulopathy Severity Predicts Hospital Mortality*
Lyons, P. G., Micek, S. T., Hampton, N. B., & Kollef, M. H. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000002997 · Cited by 157
Recombinant Thrombomodulin Protects Mice against Histone-Induced Lethal Thromboembolism
Nakahara, M., Ito, T., Kawahara, K., Yamamoto, M., Nagasato, T., Shrestha, B., Yamada, S., Miyauchi, T., Higuchi, K., Takenaka, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075961 · Cited by 156
Septic Shock — Evaluating Another Failed Treatment
Wenzel, R. P., & Edmond, M. B. (2012) · New England Journal of Medicine · doi:10.1056/nejme1203412 · Cited by 78
Cited by
van der Poll, T., Shankar-Hari, M., & Wiersinga, W. J. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.012 · Cited by 1,010
Endothelial Responses in Sepsis
Joffre, J., Hellman, J., Ince, C., & Ait-Oufella, H. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201910-1911tr · Cited by 713
Diagnosis and management of sepsis‐induced coagulopathy and disseminated intravascular coagulation
Iba, T., Levy, J. H., Warkentin, T. E., Thachil, J., van der Poll, T., & Levi, M. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14578 · Cited by 531
Self-citationPrognostic and predictive enrichment in sepsis
Stanski, N. L., & Wong, H. R. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0199-3 · Cited by 393
Signaling pathways and intervention therapies in sepsis
Zhang, Y.-Y., & Ning, B.-T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00816-9 · Cited by 349
Metadata
- Authors
- Vincent, J.-L., Francois, B., Zabolotskikh, I., Daga, M. K., Lascarrou, J.-B., Kirov, M. Y., Pettilä, V., Wittebole, X., Meziani, F., Mercier, E., Lobo, S. M., Barie, P. S., Crowther, M., Esmon, C. T., Fareed, J., Gando, S., Gorelick, K. J., Levi, M., Mira, J.-P., Opal, S. M., Parrillo, J., Russell, J. A., Saito, H., Tsuruta, K., Sakai, T., Fineberg, D., & for the SCARLET Trial Group
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2019-05-28
- Volume
- 321
- Issue
- 20
- Pages
- 1993
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2946375103
- Cited by
- 357
- References
- 9
- FWCI
- 29.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2019.5358
- The paper
- Vincent, J.-L., Francois, B., Zabolotskikh, I., Daga, M. K., Lascarrou, J.-B., Kirov, M. Y., Pettilä, V., Wittebole, X., Meziani, F., Mercier, E., Lobo, S. M., Barie, P. S., Crowther, M., Esmon, C. T., Fareed, J., Gando, S., Gorelick, K. J., Levi, M., Mira, J.-P., . . . for the SCARLET Trial Group. (2019). Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2019.5358
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.